Spinal bone metastases in colorectal cancer: a retrospective analysis of stability, prognostic factors and survival after palliative radiotherapy

Tilman Bostel¹,³, Robert Förster¹,³, Ingmar Schlamp²,³, Tania Sprave¹,³, Thomas Bruckner², Nils Henrik Nicolay¹,³, Stefan Ezechiel Welte¹, Jürgen Debus¹,³ and Harald Rief¹,³*

Abstract

Background: This retrospective analysis aimed to analyse the stability of spinal bone metastases in colorectal cancer (CRC) patients following radiotherapy (RT) by use of a validated score and to assess prognostic factors for stability and survival.

Methods: Ninety-four patients with osteolytic spinal bone metastases from CRC were treated at the Department of Radiation Oncology at the University Hospital Heidelberg between 2000 and 2014. The stability of each affected vertebral body was assessed according to the validated Taneichi bone stability score on the basis of the treatment planning CT scan prior to RT and also based on the follow-up CT examinations at 3 and 6 months after RT. Additionally, bone survival rates (time between first day of RT and death from any cause) as well as prognostic factors for bone survival were evaluated for all study patients.

Results: Before RT, 59 patients (63%) were rated unstable according to the Taneichi score. Pathological fractures within the irradiated region were diagnosed in 43 patients (46%) prior to RT. New fractures or progression of previously collapsed vertebrae were diagnosed in 4 patients (4%) after irradiation. Significant re-calcification and stabilization of former unstable bone metastases was only observed in 3/59 patients (3%) and 5/59 patients (9%). The median bone survival was 4.2 months (range 0.5–67.3 months) and 6 months after RT 61% of the patients were dead. Karnofsky performance score (KPS) (< 70% vs. ≥ 70%), chemotherapy and bisphosphonate therapy were predictive prognostic factors for bone survival.

Conclusions: Our study population is characterized by poor bone survival and low re-calcification rates of unstable spinal bone lesions 3 and 6 months after RT. To avoid unnecessary hospitalisation and improve remaining QoL, short fractionated treatment schedules of RT may be prefered in this highly palliative situation, particularly for patients with a KPS < 70%.

* Correspondence: harald.rief@med.uni-heidelberg.de

1Department of Radiation Oncology, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany
²National Center for Radiation Oncology (NCRO), Heidelberg Institute for Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120 Heidelberg, Germany

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Colorectal cancer (CRC) is one of the most common cancers worldwide, with more than 1 million new cases per year [1]. While the prognosis of CRC has improved over the last decade with the advent of neoadjuvant treatment regimes and the introduction of targeted agents, the metastatic form of CRC remains to have a poor prognosis with a 5-year survival rate of only 10% [1]. It is well known that the most common target sites for metastatic spread are the liver and the lungs [2–4]. Skeletal involvement is also a relative frequent finding in metastatic CRC, and is mostly associated with distant metastases in other organs such as liver or lung [5–7]. Up to 5, 5% of all CRC patients have bone metastases at the time of initial diagnosis and up to 27% will develop bone metastases during the course of their disease [2, 5, 6]; the most common localization of bone metastases is the vertebral column [8]. Due to novel treatment approaches for patients with metastatic CRC, the median survival of affected patients has increased significantly, and as a consequence, patients have a higher risk not only to develop bone metastases but also to experience complications arising from metastatic bone destruction, such as pain, pathological fractures, spinal cord compression or hypercalcemia [9–16]. These skeletal-related events have the potential to severely affect patients’ quality of life (QoL) [17].

The treatment of bone metastases requires a multidisciplinary approach employing surgery, systemic treatment or radiotherapy [18]. Pain, existing or impending instability, neurological symptoms due to compression of the spinal cord, or previous surgical intervention form the main indications for radiotherapy (RT). RT offers pain relief in 50–80% of patients [19].

Besides pain, impaired stability of metastatic vertebral bodies can result in severe complications and therefore strongly affect patients’ QoL. Insufficient stabilization of the metastatic vertebral column may lead to severe disability from pathologic fractures; however, commonly prescribed surgical corsets add a significant immobilization to already existing pain symptoms. Recently, we reported on patients with lung cancer, breast cancer and pelvic gynecologic malignancies in which a significant response towards RT in terms of stability could be demonstrated [20, 21, 22]. The benefit of RT concerning pain and recalcification of osteolytic metastases may be increased when the therapy is combined with concomitant administration of bisphosphonates [23, 24].

The aim of this retrospective analysis was to systematically assess the bone lesions resulting from CRC in terms of stability, fractures before and after RT, survival, and predictive factors for stability and survival.

Methods
Ninety-four patients with bone metastases of the thoracic and lumbar spine resulting from CRC were treated at the Department of Radiation Oncology at Heidelberg University Hospital between February 2000 and July 2014. Patients’ data were taken from the cancer registry of the National Center for Tumour Diseases (Heidelberg, Germany). Patients underwent regular follow-up examinations including computed tomography (CT) imaging. Diagnosis was based on CT, magnetic resonance imaging (MRI) or bone scintigraphy findings. The evaluated osteolytic bone metastases had to be located in the thoracic or lumbar spine.

The stability of each affected vertebral body was assessed according to the validated Taneichi bone stability score on the basis of the treatment planning CT scan prior to RT and also based on the follow-up CT examinations at 3 and 6 months after RT [25]. This scoring system constitutes a simple method for classifying osteolytic metastases in vertebral bodies as “stable” or “unstable” by definition of risk factors such as tumor size and the degree of costovertebral joint destruction for the thoracic region (Th 1 to 10) and tumor size and the degree of pedicle destruction for the lumbar region (Th 11 to L5).

Osteolytic metastases were rated on a scale from A to G, whereby subtypes A to C were defined as stable, and subtypes D to G as unstable (Fig. 1). In patients with more than one metastasis per vertebral body, the localization with the highest Taneichi score was assessed.

Many patients (43%) exhibited more than one affected vertebral body within the planning target volume (PTV). Accordingly, 94 patients presenting with a total of 162 bone lesions in the thoracic and lumbar spine were evaluated. The Karnofsky performance score (KPS) was used to assess performance status [26]. Many patients received further treatments such as chemotherapy or bisphosphonates before, during and after radiotherapy. The characteristics of all patients included in this study are summarized in Tables 1 and 2.

RT was planned on the basis of a planning CT examination and performed over a dorsal photon field with the energy 6 MV. PTV covered the affected vertebral body/bodies as well as the vertebral body immediately above and below. Median delivered dose was 30 Gy (range 20–40 Gy) in individual treatment fractions of 3 Gy (2–4 Gy) (Table 2).

Statistical analysis was done using the SAS software version 9.3 (SAS Institute, Cary, NC, USA). A p-value of p < .05 was considered statistically significant (Chi square and Log-rank test). Bone survival was defined as the time between first day of RT for bone metastases until death from any cause. Survival was plotted according to the Kaplan-Meier method. Bowker’s test and kappa statistics were calculated to
evaluate distribution of the Taneichi score over time. Univariate logistic regression analysis was performed to evaluate possible predictors for bone survival.

This analysis was approved by the independent ethics committee of the Heidelberg University Medical Faculty (# S-513/2012).

**Results**

The mean follow-up time was 7.5 months (range 0.5–67.3 months). Ninety-four patients with a total of 162 bone metastases (range 1–5 metastases/patient) were assessed according to the validated Taneichi scoring system prior to RT and at 3 and 6 months after RT based on CT imaging. Osseous metastases were located in the thoracic spine in 60% (n = 56) and in the lumbar spine in 40% (n = 38) of patients. Pathological fractures within the irradiated region were diagnosed in 43 patients (46%) prior to RT. New fractures or progression of previously collapsed vertebrae were diagnosed in 4 patients (4%) after irradiation.

The most frequently observed Taneichi subtype was D (31%; n = 29) (Fig. 1). None of the initially stable bone lesions were rated unstable during the course of follow-up (Table 3).

In contrast, RT could stabilize primary unstable bone metastases in 5 and 9% of patients after 3 and 6 months.
In patients with KPS \geq 70\%, the stabilization rate was higher than in patients with KPS < 70\% after 6 months (16\% vs. 0\%).

Due to relatively low stabilization rates, the planned analysis of predictive factors for stabilization was not possible. Taneichi subtypes improved in 49\% (n = 18) and showed no change in 51\% (n = 19) of the patients who were still alive 6 months after RT. No deterioration in the scored Taneichi value was observed at the follow-up examinations compared to the baseline CT scan. The Bowker test shows the distribution pattern of the subtypes according to the Taneichi score prior to and 3 and 6 months after RT (Tables 4 and 5). Asymmetry was apparent and correlation was good (weighted kappa = 0.85 and 0.63, Tables 4 and 5).

Thirty-seven patients (39\%) were still alive at 6 months after RT. The median bone survival for the entire patient cohort was 4.2 months (range 0.5–67.3 months). KPS was a strong predictive factor for bone survival (p < 0.0001) (Fig. 2). Median bone survival was 1.7 months (range 0.5–7.5 months) for patients with a KPS < 70\% in contrast to 12.4 months (range 4.3–67.3 months) for patients with a KPS of \geq 70\%.

The use of bisphosphonates and chemotherapy were further predictive factors significantly correlated with bone survival in the univariate analysis (Table 6).
prevalence of additional visceral metastases, the use of targeted agents and the number of bone metastases were not predictive for bone survival (Table 6).

Discussion

The major problems of patients with bone metastasis that commonly reduce quality of life comprise severe, drug-resistant pain symptoms, manifest or impending fractures, tumor-induced hypercalcemia and neurological complications such as paraplegia.

Therefore, classification of stability of spinal metastases is a frequent clinical concern. The Taneichi scoring system is an established tool for the classification of spinal metastases regarding risk of pathological fracture or bone instability.

In previous studies, therapeutic effects of palliative RT on colorectal spinal metastases were only measured in terms of pain control and improvement of neurological deficits due to metastatic spinal cord compression [27]. In contrast, there are no existing data concerning the impact of RT on the stability of spinal metastases due to colorectal cancer.

Prior to RT, 63% of the patients in this dataset had unstable bone metastases of the thoracic or lumbar spine. After 6 months, palliative RT reached significant reossification and stabilization in only 9% of these bone lesions.

The reported stabilization rate is relatively poor compared to the stabilization rate of other tumor entities after palliative RT such as lung or breast cancer and pelvic gynecological malignancies [19, 22, 23]. In contrast, spinal metastases from malignant melanoma and renal cell carcinoma do not benefit at all from palliative RT with regard to re-calcification and stabilization of unstable spinal bone lesions [28, 29].

In our study, the poor stabilization effect of palliative RT can be explained to a large extent by the limited life expectancy of the patients. At 6 months after RT, only 39% of patients were still alive. Median survival was 4.2 months after diagnosis of bone metastasis and corresponds well with the results of previously reported patient cohorts [6, 30, 31]. The very poor bone survival of CRC patients is explained by the fact that bone metastasis from CRC represents a late event in the evolution of the disease, with the majority of the patients exhibiting widely disseminated disease at the time of first diagnosis of skeletal manifestation [6, 7].

In line with the results of another study [27], we identified the patients’ performance status as a prognostic factor for predicting bone survival in CRC patients. A Karnofsky performance status (KPS) < 70%

### Table 5 Test of symmetry for Taneichi score (6 months)

| Subtypes before RT | A | B | C | D | E | F | G | Total |
|--------------------|---|---|---|---|---|---|---|------|
| A                  | 2 | 0 | 0 | 0 | 0 | 0 | 2 |      |
| B                  | 5 | 1 | 0 | 0 | 0 | 0 | 6 |      |
| C                  | 3 | 3 | 1 | 0 | 0 | 0 | 7 |      |
| D                  | 1 | 0 | 3 | 9 | 0 | 0 | 13|      |
| E                  | 1 | 0 | 1 | 3 | 0 | 0 | 5 |      |
| F                  | 0 | 0 | 0 | 1 | 2 | 0 | 3 |      |
| G                  | 0 | 0 | 0 | 0 | 0 | 1 | 1 |      |
| Total              | 12| 4 | 4 | 10| 4 | 2 | 1 | 37   |

This Bowker Test shows the distribution of subtypes of Taneichi-Score before and 6 months after RT. Deterioration of Taneichi-subtypes occurs in no cases, improvement in 49% (n = 18), No change is seen in 51% (n = 19) of the patients who were still alive more than 6 months after RT.

Abbreviation: RT radiotherapy

![Fig. 2 Bone survival depending on the Karnofsky performance score (KPS)](image-url)
Table 6 Results of prognostic factors related to bone survival

| Parameter                          | p-value | HR     | CL     |
|-----------------------------------|---------|--------|--------|
| Karnofsky PS (≥ 70% vs. < 70%)     | < 0.0001| 26.85  | 10.95–65.87 |
| Chemotherapy (yes vs. no)         | < 0.01  | 0.49   | 0.29–0.84 |
| Targeted agents (yes vs. no)      | n.s.    | 0.83   | 0.43–1.6 |
| Bisphosphonate therapy (yes vs. no)| < 0.05  | 0.5    | 0.28–0.89 |
| Visceral metastases (yes vs. no)  | n.s.    | 2.07   | 0.88–4.9 |
| Number of bone metastases (1 vs. > 1) | n.s.    | 1.32   | 0.83–2.1 |

**Abbreviations:** Karnofsky PS, Karnofsky performance score. HR, Hazard Ratio; CI, Confidence Limits of the results for a confidence level of 95%. n.s. not significant

was significantly associated with an extremely poor bone survival of less than 2 months. In contrast, patients with a KPS ≥ 70% had a bone survival of about 12 months. As recalcification of irradiated osteolytic bone lesions usually takes up to several months, it is unlikely that patients with a KPS < 70% will have a benefit in terms of stabilization. In contrast, patients with a KPS ≥ 70% have a higher chance for stabilization due to longer life expectancy and continued mobility-related physical strain to the bones. In our cohort, 4 out of 25 patients (16%) with initially unstable bone lesions and a KPS < 70% were found stabilized by RT within 6 months.

Additionally, our results showed that patients with chemotherapy and/or bisphosphonate therapy had an improved bone survival compared to patients without these therapies. In 81% of patients, bisphosphonates were initiated after the end of radiotherapy. In contrast, chemotherapy was started prior to RT in 93% of patients.

In contrast, the absence or presence of visceral metastases, the number of bone metastases and the use of targeted agents were not statistically significant in the univariate analysis.

Our study has several limitations, among them the retrospective character of the dataset. Secondly, due to the limited number of patients, a statistically sound multivariate analysis of prognostic factors for bone survival was not possible. Additionally, the selection criteria for the application of chemotherapy and bisphosphonates were retrospectively not available; therefore, we cannot rule out that the use of both treatment modalities may be related to a better performance status rather than being an independent predictive factor for bone survival. A planned analysis of prognostic factors for stabilization of initially unstable bone metastases was not possible due to the poor bone survival and low bone recalcification rates at 3 and 6 months after RT. Due to the limitations of the Tanoueichi score, patients with bone metastases from CRC outside the thoracic and lumbar spine were not considered.

Summarized, due to the low recalcification rates observed in our patient cohort, short course RT appears preferable for patients with a KPS < 70%, since it provides similar pain control as protracted schedules. In contrast, patients with a KPS ≥ 70% may be treated with more protracted radiation schedules, if the treatment goal is stabilization, even though the chance for attaining this objective is relative small compared to other tumor entities [22, 23].

**Conclusion**

Patients with bone metastases due to CRC exhibit poor bone survival and low recalcification rates of unstable spinal bone lesions at 3 and 6 months after RT. To avoid unnecessary hospitalisation and improve QoL, short fractionated treatment schedules of RT may be preferable in this highly palliative situation, particularly for patients with a KPS < 70%.

**Acknowledgements**

We thank our German Bone Cancer Research Group Members for their great effort.

**Funding**

Not applicable.

**Availability of data and materials**

The data used in this analysis is from publications available in the public domain.

**Authors’ contributions**

TB and HR developed and planned the retrospective analysis. TBBr is responsible for statistical considerations/basis of the analysis. RF, IS, TS, NNN, SEW, JD and HR participated in data collection and interpretation of the results. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**

The Heidelberg Ethics Committee approved this study on 22 October 2012. Due the retrospective design, informed consent was not required.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**

1. Department of Radiation Oncology, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.
2. Department of Medical Biometry, University Hospital Heidelberg, Heidelberg, Germany.
3. National Center for Radiation Oncology (NCRO), Heidelberg Institute for Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.

**Received**: 15 March 2017 **Accepted**: 4 July 2017

**Published online**: 11 July 2017

**References**

1. Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 2009;22(4):191–7.
2. Disibio G, French SW. Metastatic patterns of cancers: results from a large autopsy study. Arch Pathol Lab Med. 2008;132(6):931–9.
3. Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, Abbruzzese JL. Metastatic patterns in adenocarcinoma. Cancer. 2006;106(7):1624–33.
4. Weiss L, Grundmann E, Tothorst J, Hertveit F, Moberg I, Eder M, Fenoglio-Preiser CM, Napier J, Home CH, Lopez MJ, et al. Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol. 1986;150(3):195–203.
5. Katoh M, Unakami M, Hara M, Fukuchi S. Bone metastasis from colorectal cancer in autopsy cases. J Gastroenterol. 1995;30(5):615–8.
6. Roth ES, Fetzer DT, Barron BJ, Joseph UA, Gayed IW, Wan DQ. Does colon cancer ever metastasize to bone first? a temporal analysis of colorectal cancer progression. BMC Cancer. 2009;9:274.
7. Kanthan R, Loewy J, Kanthan SC. Skeletal metastases in colorectal carcinomas: a Saskatchewan profile. Dis Colon Rectum. 1999;42(12):1592–7.
8. Baek SJ, Hur H, Min BS, Baik SH, Lee KY, Kim NK. The characteristics of bone metastasis in patients with colorectal cancer: a long-term report from a single institution. World J Surg. 2016;40(4):982–8.
9. Douillard JY, Siena S, Cassidy J, Tabernero J, Burke R, Baruqel M, Hambert Y, Bodoky G, Cunningham D, Jassem J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010;28(34):4697–705.
10. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Williamson SK, Findlay BP, Ptot HC, Alberts SR. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22(1):23–30.
11. Saltz LB, Clarke S, Diaz-Rubio E, Schellenvaer F, Figer AW, Koski S, Lichinetti M, Yang TS, Rivera F, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26(12):2013–9.
12. Tourignand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Busey M, Ganem G, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22(2):229–37.
13. Van Cutsem E, Knohe CH, Hitre E, Zaluski J, Chang Chen CR, Makhson A, D’Haens G, Pinter T, Lim R, Bodoky G, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408–17.
14. Stintzing S, Grothe A, Hendrich S, Hoffmann RT, Heinemann V, Rentsch M, Fuenweger C, Muacevic A, Trumm CG. Percutaneous radiofrequency ablation (RFA) or robotic radiosurgery (RRS) for salvage treatment of colorectal liver metastases. Acta Oncol. 2013;52(5):971–7.
15. Scheele J, Stangl R, Attendorn-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg. 1990;77(11):1241–6.
16. Comito T, Cozzi L, Gletici E, Campisi MC, Liardo RL, Navarria P, Ascolese A, Tozzi A, Iftode C, De Rose F, et al. Stereotactic Ablative Radiotherapy (SABR) and we will help you at every step:

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit